Curanex Pharmaceuticals Inc (CURX)
| Market Cap | 7.39M |
| Revenue (ttm) | n/a |
| Net Income | -10.47M |
| EPS | -7.57 |
| Shares Out | 1.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,570 |
| Open | 5.100 |
| Previous Close | 5.270 |
| Day's Range | 4.700 - 5.380 |
| 52-Week Range | 3.576 - 183.592 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About CURX
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New ... [Read more]
Financial Performance
Financial StatementsNews
Curanex Pharmaceuticals Inc trading halted, news pending
19:50 EDT Curanex (CURX) Pharmaceuticals Inc trading halted, news pending
Curanex Pharmaceuticals Quarterly report: Q2 2026
Curanex Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associate...
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease
Curanex highlights patient case study in treatment of cancer cachexia
Curanex (CURX) highlighted a patient case study that management believes further supports the company’s strategic interest in treatment of cancer cachexia. The company said, “The case involved “Johnny...
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology's most serious and underserved supportive-care markets
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company
Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Cura...
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform
Curanex completes dose-range finding toxicology study of Phyto-N
Curanex (CURX) Pharmaceuticals announced the successful completion of a dose-range finding toxicology study of its lead botanical drug candidate, Phyto-N, conducted in Sprague-Dawley rats and dogs. Th...
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18, ...
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy
Curanex appoints two research experts to board of directors
Curanex Pharmaceuticals (CURX) announced the appointment of two life sciences research experts to the Company’s Scientific Advisory Board. Daniel Pascheles is Former CEO and Partner at Molekule Consul...
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq:...
Curanex announces formation of Scientific Advisory Board
Curanex (CURX) Pharmaceuticals announced the formation of a new Scientific Advisory Board, reporting to and supporting the executive team and Board of Directors of Curanex. The Scientific Advisory Boa...
Curanex Forms World Class Scientific Advisory Board
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”...
Curanex provides operational update on regulatory milestones
Curanex (CURX) Pharmaceuticals announced the completion of a Good Manufacturing Practice-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This pilot marks a key manufacturing...
Curanex Provides Operational Update on Key Regulatory Milestones
Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” o...
Curanex engages Strategic Investor Relations to enhance Curanex’s visibility
Curanex (CURX) Pharmaceuticals has engaged Strategic Investor Relations, a premier investor relations firm, to enhance Curanex’s visibility in the financial community and support its ongoing efforts t...
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement
Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and d...
Curanex Pharmaceuticals Inc trading resumes
11:33 EDT Curanex (CURX) Pharmaceuticals Inc trading resumes
Curanex Pharmaceuticals Inc trading halted, volatility trading pause
11:18 EDT Curanex (CURX) Pharmaceuticals Inc trading halted, volatility trading pause
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and ...
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering
Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and d...
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and d...
Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO
Curanex Pharmaceuticals, a preclinical biopharma developing botanical-based treatments for various diseases, filed on Wednesday with the SEC to raise up to $10 million in an initial public offering.